Aldeyra Therapeutics, Inc. (ALDX) SEC Filings & Earnings Calls
EquiReason read 11 Aldeyra Therapeutics, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-29 — Aldeyra Therapeutics announces intent to submit Formal Dispute Resolution Request (FDRR) to FDA's Office of New Drugs appealing Complete Response Letter for reproxalap (dry eye dis.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 39.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
29 Sep 20268-K · 7.01, 8.01Aldeyra Therapeutics announces intent to submit Formal Dispute Resolution Request (FDRR) to FDA's Office of New Drugs appealing Complete Response Letter for reproxalap (dry eye disease). Cash runway extended into 2029.open
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q2-2026 | $45M |
Risks flagged
Regulatory risk: reproxalap NDA denied three times; FDRR outcome uncertain.
“Received three Complete Response Letters; FDRR submission expected in Q4 2026.”
6 Aug 202610-QQ2 2026 net loss improved to $5.5M from $9.8M YoY; cash burn continues; debt fully repaid; AbbVie option not exercised.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q2-2026 | $45M | |
| Net loss · Q2-2026 | $5M | -44% y/y |
| Research and development expense · Q2-2026 | $3M | -59% y/y |
| General and administrative expense · Q2-2026 | $2M | +42% y/y |
| Net loss per share - basic and diluted · Q2-2026 | $0.09 | -44% y/y |
Risks flagged
No approved products; reliance on future financing
“We have no products approved for sale in the United States or elsewhere.” · word for word
AbbVie option may not be exercised
“As of August 6, 2026, AbbVie has not exercised the AbbVie Option.” · word for word
Securities class action lawsuit
“On March 30, 2026, a purported stockholder filed a putative class action lawsuit ... we cannot reasonably predict the outcome or estimate potential losses.” · word for word
15 Jul 20268-K · 8.01Aldeyra Therapeutics received FDA minutes from a Type A meeting regarding reproxalap NDA resubmission for dry eye disease; plans to request a Type D meeting.open
Risks flagged
Regulatory uncertainty; no assurance of NDA resubmission approval.
“Potential resubmission of the NDA... no guarantee of success.”
7 May 202610-QQ1 2026 net loss decreased 65.2% to $3.5M, driven by lower R&D and G&A expenses; cash runway extended into H2 2028.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q1-2026 | $65M | |
| Net loss · Q1-2026 | $-3M | -65% y/y |
| Research and development expenses · Q1-2026 | $2M | -68% y/y |
| Total debt · Q1-2026 | $15M | |
| Net loss per share - basic and diluted · Q1-2026 | $-0.06 | -65% y/y |
Risks flagged
FDA Approval Risk for Lead Asset
“On March 17, 2026, we announced that we had received a Complete Response Letter from the FDA (the 2026 Complete Response Letter). The 2026 Complete Response Letter stated that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have un” · word for word
Collaboration/Commercialization Risk
“As of May 7, 2026, AbbVie has not exercised the AbbVie Option.” · word for word
Litigation Risk
“On March 30, 2026, a purported stockholder filed a putative class action lawsuit (the Securities Class Action) in the U.S. District Court for the District of Massachusetts, against us and certain current and former officers.” · word for word
Financing Risk
“We will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order for the Company to carry out all of the planned research and development activities and regulatory activities” · word for word
1 May 20268-K · 7.01Aldeyra released a corporate overview disclosing standardized treatment estimates and confidence intervals for reproxalap dry eye disease trials, and its interpretations of FDA positions on primary endpoints, ahead of a potential NDA resubmopen
Risks flagged
Regulatory risk: FDA may not agree with Aldeyra's interpretations of primary endpoints, potentially delaying or preventing NDA resubmission and approval.
“Aldeyra’s abbreviated interpretations of the U.S. Food & Drug Administration positions on the primary endpoints for the reproxalap clinical trials, as well as the Aldeyra positions on the primary endpoints.” · word for word
27 Feb 202610-K10-K filing with clear regulatory setback and financial position details, but no quantified guidance or trend signals.open
Risks flagged
Regulatory approval risk for reproxalap
“FDA issued a CRL stating the NDA did not demonstrate efficacy in treating ocular symptoms associated with dry eyes.”
Liquidity and going concern risk
“We will need to raise additional capital in the form of debt or equity or through partnerships to fund additional development.”
Dependence on AbbVie option exercise
“If the AbbVie Option is not exercised, we will be responsible for funding further development and commercialization of reproxalap.”
5 Nov 202510-QQ3 2025 net loss decreased significantly year-over-year due to lower operating expenses; no revenue reported.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q3-2025 | $59M | |
| Marketable securities · Q3-2025 | $16M | |
| Net loss · Q3-2025 | $8M | -49% y/y |
| Research and development expense · Q3-2025 | $5M | -56% y/y |
| General and administrative expense · Q3-2025 | $3M | -31% y/y |
Risks flagged
Funding dependency
“The Company will need to secure additional funding in the future... Additional funding may not be available to the Company on acceptable terms, or at all.” · word for word
Clinical-stage development risk
“The Company is a clinical-stage biotechnology company... Inability to secure additional funding could delay, reduce, or eliminate research and development programs and reproxalap commercialization efforts.”
Aldeyra Therapeutics, Inc. — questions
- What did Aldeyra Therapeutics, Inc. file recently?
- 11 SEC filings in the last 12 months. Latest: 8-K on 2026-09-29 — Aldeyra Therapeutics announces intent to submit Formal Dispute Resolution Request (FDRR) to FDA's Office of New Drugs appealing Complete Response Letter for reproxalap (dry eye disease). Cash runway extended into 2029.
Every figure on this page comes from Aldeyra Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.